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Racial and Ethnic Disparities in the Use of Drug Therapy
* 
 
The purpose of this research is to explain the variation in the utilization of drug therapy for the 
medical conditions of depression, high cholesterol, and hypertension between Hispanics, 
non-Hispanic blacks, and non-Hispanics whites using Oaxaca-type decomposition analysis 
based on logit estimates. We find that almost the entire share of the utilization differences in 
drug therapy between blacks and whites can be explained by the differences in the 
coefficients of observable characteristics, while the sources of the utilization difference 
between the whites and Hispanics are split between the differences in the observable 
characteristics and the coefficient estimates. This result implies that strategies to improve 
racial and ethnic disparities need to be tailored to each group by focusing on the specific 
factors that are attributed to causing the disparity. 
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1. Introduction 
  The existence of racial and ethnic disparities in healthcare has been widely reported (e.g., 
Trivedi et. al, 2005).  Variations in the access and utilization of drug therapy for chronic 
conditions by race/ethnicity can lead to significant health outcomes differences and higher health 
care costs.  These disparities are of significant policy concern because public sources pay for a 
substantial portion of health care costs. This has led to a call to study the existence of disparities 
and identify potential areas in which intervention strategies can be developed (see Smedley et al, 
2003; Anderson et al, 2004; National Research Council, 2004).  Although many studies have 
confirmed the existence of racial/ethnic disparities (Agency for Healthcare Research and Quality, 
2005; Jha et al, 2005; Trivedi et al, 2005; Han and Liu, 2005), the causes of disparities in the use 
of drug therapy remains understudied. 
Multiple studies have documented the size of the racial/ethnic disparity in the use of 
prescription drugs, with most studies comparing the outcomes of the Hispanic and non-Hispanic 
black populations to the outcomes of the non-Hispanic white population.
1  Schore, Brown, and 
Lavin (2004) examined the number of prescription drugs used by racial/ethnic groups among 
individuals that are dually eligible for Medicare and Medicaid.  They found statistically 
significant differences in the use of prescription drugs, with blacks filling 0.8 fewer prescriptions 
per month than whites.  Although there is variation in the use of prescription drugs, differences 
in total number of prescriptions filled do not necessarily prove the existence of a disparity if the 
underlying need for prescription drugs are different.   
By studying disparities in the receipt of drugs for specific medical conditions, Schneider, 
Zaslavsky, and Epstein (2002) found blacks were less likely than whites to receive a beta-blocker 
                                                 
1 Throughout the paper the word “non-Hispanic” has been omitted when referring to non-Hispanic blacks and non-
Hispanic whites 3 
 
after a heart attack.  For Medicare beneficiaries with diabetes, heart disease, and hypertension, 
Briesacher, Limcangco, and Gaskin (2004) examined differences in the receipt and amount spent 
on prescription drugs.  They compared people with similar Medicare supplemental insurance and 
found statistically significant differences in the use of prescription drugs by race/ethnicity for 
aggregate use and for specific medical conditions.  Similarly, Han and Lui (2005) found 
disparities in the use of mental illness drugs among people with self-reported mental illnesses 
and Gonález et al. (2008) found that difference in the percentage of black patients with major 
depressive disorder that use an antidepressant is 22.7 percentage points lower than for whites. 
  A significant number of papers showing the existence of racial/ethnic disparities rely on 
statistical models which include a binary indicator for race/ethnicity as an explanatory variable in 
addition to other controlling factors.  This method allows for verification of the existence of a 
disparity but constrains the coefficient estimates for these other factors to be the same across 
groups.  That is, this method overlooks the possibility that socio-economic attributes may 
differently contribute to the decision of whether or not to adhere to drug therapy by groups.  It 
has long been understood that racial/ethnic status impacts health outcomes, but these effects 
interact with the socioeconomic status of the individual. For example, research on infant and 
mortality rates by racial/ethnic groups has found that Hispanics generally have better health 
outcomes than blacks even though they have similar socioeconomic status (Palloni and 
Morenoff, 2001; Palloni and Arias, 2004; Markides and Eschbach, 2005; Hummer et al., 2007).  
When studying the sources of the disparity, it can be better understood by separating the 
disparity into two effects using Oaxaca-type decomposition based on separate estimates for each 
group: the characteristics effect and the coefficients effect (see Oaxaca (1973) for explanation of 
the two effects).   4 
 
The characteristics effect measures how differences in the characteristics of each group 
affect the difference in the dependent variable.  For example, suppose that younger individuals 
with depression are less likely to use an antidepressant.  If whites are older than Hispanics on 
average, the characteristics effect would explain how much of the difference in utilization 
between whites and Hispanics of antidepressants is due to differences in age composition.  In 
contrast, the coefficients effect measures the impact of variation in the parameter estimates on 
differences in utilization when separate regressions are estimated for each group.  Suppose that 
white males are more likely to receive hypertensive drugs than black males, even though both 
have the same characteristics.  Then the coefficients effect measures the contribution of the 
difference in the two coefficient estimates to the overall difference in the hypertension drug 
utilization by the two groups.
2   
Recently, the use of Oaxaca decomposition has increased in popularity for studying 
disparities, particularly in the health care literature.  Decomposition analysis has been used to 
study racial/ethnic disparities in access to health insurance (Pylypchuk and Selden, 2008; 
Zuvekas and Taliaferro, 2003; Thomasson, 2006),
3 while a study by Jacobson et al. (2007) used 
Oaxaca decomposition to study the completion of substance abuse treatment programs.  
Although the technique has gained in popularity, it has not been extensively used to study drug 
therapy.  
In this paper, we investigate the sources of the variation in prescription drug therapy use 
rates for three groups, non-Hispanic whites, non-Hispanic blacks, and Hispanics, using a 
straightforward Oaxaca-type decomposition method based on non-linear estimation (Yun, 2004).  
One nice feature of the employed decomposition method is that it enables us to measure the 
                                                 
2The variation of coefficients by group may be arisen by several causes such as differences in behavior and 
discrimination. 
3 See Mayberry et al (2000) and Weineck et al (2000) for a discussion of disparities in health insurance coverage.   5 
 
magnitude of the characteristics and coefficients effects of individual factors.  This in turn allows 
public policy makers to identify target variables whose values and effects are contributing to 
racial/ethnic disparities, and to devise policies to reduce discrepancies in modifiable 
characteristics.  
We focus on the receipt of prescription drugs for depression, high cholesterol, and high 
blood pressure, also known as hypertension, using samples from the Medical Expenditures Panel 
Survey (MEPS).
4  These diseases are prevalent in the United States, have clear pharmacological 
practice guidelines, and have significant mortality and quality of life implications.  For example, 
depression is the fourth leading cause of non-fatal disease burden (Üstün et al, 2004) and the 
standard pharmaceutical treatment for depression is antidepressants.
5  In contrast, high 
cholesterol and high blood pressure are two of the main risk factors for heart disease (Kaiser 
Family Foundation, 2007) and also have standard drug treatment guidelines.
6  Further, 
mismanagement of these conditions due to failure to adhere to the drug therapy can lead to 
increased health care costs in the future.   
We study various medical conditions as robustness checks, which allow us to determine 
if disparities are similar or different across medical conditions and to determine if intervention 
strategies to reduce disparities would be effective across various drug treatments.  Our results 
                                                 
4 We focus on the racial and ethnic gaps in the receipt of antidepressant drug therapy for depression while studying 
the receipt of drugs for high cholesterol and high blood pressure to determine if disparities follow similar patterns 
for other medical conditions. 
5 The treatment guidelines are available in Practice Guidelines for Treatment of patients with major depressive 
disorder, second edition (http://www.psychiatryonline.com/pracGuide/loadGuidelinePdf.aspx?file=MDD2e_05-15-
06). 
6 The treatment guidelines for high cholesterol are available in Third report of the expert panel on detection, 
evaluation, and treatment of high blood cholesterol in adults (adult treatment panel III) executive summary 
(http://www.nhlbi.nih.gov/guidelines/cholesterol/atp3xsum.pdf). Standard pharmacological treatment includes the 
use of statins, such as Lipitor or Zocor.
 Treatment guidelines for high blood pressure are available in Seventh Report 
of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC 
7) Express (http://www.nhlbi.nih.gov/guidelines/hypertension/express.pdf). Standard pharmacological treatment 
includes the use of a beta-blocker and/or angiotensin-converting enzyme (ACE) inhibitor or its close cousin the 
angiotensin II receptor blocker (ARB).  In the analysis, receipt of a hypertensive drug is defined as obtaining either a 
beta-blocker or ACE/ARB. 6 
 
suggest that almost the entire share of the utilization differences in drug therapy between blacks 
and whites can be explained by the differences in the coefficients of observable characteristics.  
Policy should focus on educating blacks of the danger of not adhering to the drug therapy since 
blacks and whites with similar characteristics, even with the same education and insurance 
coverage, behave significantly different.  In contrast, the utilization differences between the 
whites and Hispanics are caused by both differences in the observable characteristics and 
differences in the coefficient estimates.  Public policy makers should pay attention to providing 
Hispanics with better insurance coverage and improving schooling attainment in order to reduce 
the disparity. 
 
2. Data  
  The 2002 Medical Expenditures Panel Survey (MEPS) is the data source used to analyze 
the racial/ethnic disparities in the use of prescription drugs for three common medical conditions.  
We created three mutually-exclusive racial and ethnic groups as recommended by minority 
health task groups to identify Hispanic Americans independently of race: non-Hispanic whites, 
non-Hispanic blacks, and Hispanics (Zambrana and Carter-Pokras, 2001).
7  The sample for each 
medical condition is constructed from people over the age of 18 that have an affirmative 
response to the self-reported question of being told by a doctor they had the specific medical 
condition in the last year.  For example, this means the depression sample consists of individuals 
over the age of 18 that have self-reported being told by a doctor they have depression.
8  Once 
each sample is identified, the prescription medicine event file is used to determine if the 
                                                 
7 Although there is significant heterogeneity within racial and ethnic groups, MEPS does not provide the specificity 
to identify racial and ethnic subgroups.  
8 This definition eliminates the use of the drug therapies for other indications or off-label uses.  For example, a 
person who takes antidepressant for smoking cessation or anxiety would not be included in the sample.   7 
 
individual received any prescription drug for the medical condition from a list of brand and 
generic names for antidepressants, statins, and hypertensive drugs.  An individual is determined 
to receive drug treatment if they received any drug in the drug class.   
Table 1 reports the proportion of people that received drug treatment for each condition, 
broken down by race/ethnicity.  Depressed blacks and Hispanics are less likely to fill an 
antidepressant than depressed whites.  The difference in the proportion of whites and blacks that 
received an antidepressant is 16.7 percentage points, while the difference between whites and 
Hispanics is 21.5 percentage points.  Disparities are also found in individuals diagnosed with 
high cholesterol.  The difference in the proportion of people with high cholesterol that received a 
statin is 4.0 percentage points between blacks and whites and 14.3 percentage points between 
Hispanics and whites.  On the other hand, the disparity relative to whites is larger for blacks than 
Hispanics in the use of hypertensive drugs for those diagnosed with high blood pressure.  The 
unadjusted difference between white and black use of hypertensive is 14.7 percentage points, 
while the difference is only 4.9 percentage points for Hispanics and whites.   
<INSERT TABLE 1> 
In addition to the race/ethnicity factor, other factors which determine pharmacological 
utilization are divided into six groups: demographic characteristics, education, income, obesity, 
health status and insurance, and location.  The demographic characteristics used in the regression 
are age, gender, and marital status.  Higher socio-economic status is positively correlated with 
adherence to physician’s orders and health outcomes.  Socio-economic status is measured by 
income and education, which is classified into below high school degree, high school degree, and 
at least some college.   8 
 
Besides demographics and socio-economic status, the health status of an individual could 
influence the use of medications.  First, obesity is known to increase the risk of heart disease and 
is associated with depression.  To measure obesity, body mass index (BMI) is used to classify 
people into normal, overweight (BMI 25.0-29.9), and obese (BMI ≥ 30.0) weight groups.  
Second, self-reported health status is used to measure the perceived health status.  People who 
perceive their health to be poor may be more likely to use drug therapy to improve their health.  
Two self-reported health variables are used: poor physical health and poor mental health.
9  For 
each variable, an individual is classified as being in poor health if they did not report their health 
status as "good" or “excellent”.  The final measure of health status used is the number of heart 
disease conditions.  Each individual self-reports if they have a history of high blood pressure, 
coronary artery disease, angina, and heart attack.  This measure is constructed from summing 
over the number of affirmative responses.
10  Recently, it is suggested that there may be a link 
between heart disease and depression (Zellweger et al, 2004).   
The final two factors that could influence drug utilization are health insurance coverage 
and regional variation.  Insurance facilitates access to care by lowering the out-of-pocket cost to 
see a physician and purchase prescription drugs.  Although health insurance has been shown to 
improve health outcomes, the quality of health insurance coverage varies significantly in terms 
of premium cost, breath of services and providers covered, and cost-sharing. For example, 
Medicaid is insurance that covers the poor.  One concern with Medicaid is that it reimburses 
physicians at low rates.  This causes many physicians to either not accept Medicaid or locate into 
neighborhoods that have fewer Medicaid recipients.  If Medicaid disproportionally covers one 
racial or ethnic group, this could lead to disparities.  To capture differences in insurance 
                                                 
9 Self-reported mental health status is only used in the regression analysis for the depression sample. 
10 In the case of the hypertension sample, hypertension is excluded in the calculation of the number of heart disease 
conditions.   9 
 
coverage, indicator variables are created for coverage by Medicare, Medicaid, and private 
insurance, during the year.  Finally, there may be regional variation in the use of health care.  
Regional variation is captured through indicator variables for living in a metropolitan statistical 
area and region of the country: Northeast, Midwest, South, and West.  
For brevity, we only report the sample statistics for the depression sample (Table 2).  The 
patterns tended to be similar for the high cholesterol and hypertension samples across 
race/ethnicity.  Whites tend to be male, older, and have higher incomes and education levels than 
blacks and Hispanics.  Further, whites are less likely to be overweight or obese and are less 
likely to report poor health status than minorities.  There is also significant variation in the rates 
of coverage by health insurance.  Nearly seventy percent of whites have private insurance, 23.3% 
have Medicare, and 16.9% have Medicaid.  Blacks and Hispanics are less likely to have 
Medicare or private insurance.  In fact, fewer than forty percent of blacks and Hispanics have 
private insurance, but 44.9% of blacks and 35.5% of Hispanics have Medicaid.  The social 
insurance program of Medicaid covers more blacks and Hispanics compared to the general 
population and the low reimbursement rates associated with the program may explain some of 
the disparity between whites and minorities. 
<INSERT TABLE 2> 
 
 3. Estimation 
Typically, disparities between groups are identified by regressing the outcome of interest 
against racial/ethnicity indicator variables and other covariates (so-called treatment effect model).  
A statistically significant coefficient for the race/ethnicity variables indicates there may be a 
disparity.  We first follow this strategy by estimating logit models with a binary variable of the 10 
 
use of a prescription drug in the drug class as the dependent variable for each medical condition 
sample. 
Although estimation of the logit regression for the treatment effects model will identify 
the existence of differences in the outcome by group after controlling other factors, the method 
constrains the coefficient estimates for these other factors to be the same across race/ethnicity.  
Alternatively, we may estimate separate regressions for each group, which allows the 
coefficients to vary by group but complicates interpretation of the size and cause of the 
disparities.  Based on the regressions for each group, an Oaxaca-type decomposition is used to 
account for gaps in drug use.  This allows us to separate the disparity into two separate effects: 
the characteristics effect due to differences in covariate composition and the coefficients effect 
due to differences in effects of covariates, i.e., logit coefficients. 
We implement Oaxaca-type decomposition equations for discrete dependent variables as 
suggested by Yun (2004).  Previously, the difference in the mean value of a binary dependent 
variable was decomposed by so-called “simulation” (see Abowd and Killingsworth 1984; Fairlie 
2005).  For example, discrete choice models are estimated for each group, and one groups’ 
coefficients substituted with those of the other group in order to calculate a counter-factual 
predicted probability.  The coefficients effect equals the difference between the counter-factual 
prediction and the observed probability for the former group, holding characteristics constant.  
This simulation method suffers from several limitations.  Not only is it tedious but also 
problematic because it may be sensitive to the order of the switching (see Ham, Svejnar and 
Terrell 1998, p. 1137 for a discussion of path-dependency). Yun (2004) proposes a 
decomposition method that provides a systematic treatment for differences in binary outcomes 11 
 
that is free of path dependency.
11  
As discussed above, we estimate logit models of drug therapy for each race/ethnicity 
separately, where the dependent variable has a value of one if the patient received a treatment 
and the sample is restricted to patients that self-reported having the specific medical condition.  
Formally, we assume that there is a latent variable of receiving drug therapy which is specified 
as follows suppressing a racial/ethnic subscript,  i i i u X T   
* , where  i X  is a  K  1 vector of 
independent variables,  is a  1  K  vector of coefficients.  What we observe is a dummy variable 
i T , whose value is one if   0
*  i T  and zero otherwise. The likelihood of receiving drug therapy 
for patient i ( 1  T ) is estimated by ) (  i X F , where F  is the logistic distribution function, that is, 
)] exp( 1 /[ 1 ) (   i i X X F    .  The observed drug therapy rate is equal to the sample average of 











) (   .  Algebraically, the 
differences in the average likelihood of drug therapy between whites (group A) and 
blacks/Hispanics (group B) may be decomposed as following: 
], ) ( ) ( [ ] ) ( ) ( [ B B A B A B A A B A X F X F X F X F T T           
where the first and the second components in the right hand side represent the characteristics 
effect and coefficients effect, and the “over bar” represents the value of the sample’s average.  
  The above decomposition gives us the overall coefficients and characteristics effects.  To 
find the relative contribution of each variable to the treatment gap, in terms of characteristics and 
                                                 
11 What Yun (2004) proposed is a general method to decompose differences in the first moment for nonlinear 
models which have already been applied to count-data model (Park and Lohr, 2008) and hazard rate model (Powers 
and Yun, 2009) in addition to probit/logit models.  See Pylypchuk and Selden (2008) for pros and cons of existing 




coefficients effects, we employ a decomposition equation proposed by Yun (2004);
12 
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  In the receipt of antidepressants, both blacks and Hispanics have lower treatment rates 
relative to whites conditional on having depression (Table 1).  Logit regressions are used to 
identify which factors predict the use of antidepressants among those diagnosed with depression 
(Table 3).  The first two columns of the table report the estimated coefficients and marginal 
effects for the pooled sample, while the remaining columns report the results for each 
                                                 
12 In order to obtain a proper weight, the following approximations are used; first, an approximation of the value of 
the average of the function,  ) (  X F , with that of the function evaluated at the average value of exogenous 
variables,  ) (  X F ; second, a first order Taylor expansion to linearize the characteristics and coefficients effects 
around  A A X  and  B B X  .  See Yun (2004) for details. 
13  For computing asymptotic standard errors of the characteristics and coefficients effects, see Yun (2005a).  We 
deal with robustness issues, known as the index or parameterization problem and the identification problem in 
detailed decompositions. A decomposition equation with a different parameterization, that 
is, ] ) ( ) ( [ ] ) ( ) ( [ B A A A B B B A X X X X            , is possible; our results with it are not substantially 
different from those presented here and are available from the authors upon request.  Another issue when 
interpreting the decomposition results is that the coefficients effect in the detailed decomposition is not invariant to 
the choice of omitted groups when dummy variables are used (see Oaxaca and Ransom 1999, for details of this 
issue).  We follow a solution suggested by Yun (2005b, 2008) that, if alternative reference groups yield different 
estimates of the coefficients effects for each individual variable, it is natural to obtain estimates of the coefficients 
effects for every possible specification of the reference groups and take the average of the estimates of the 
coefficients effects with various reference groups as the “true” contributions of individual variables to differentials.  
While appearing cumbersome, this can be accomplished with a single estimation. We can transform our logit 
estimates into a normalized equation and use the normalized equation for our decomposition.  13 
 
racial/ethnic group.  For the pooled regression, even after controlling for observable factors, the 
disparity is found to exist for both blacks and Hispanics.  Consistent with the pattern found by 
Han and Lui (2005), the percentage of blacks that use antidepressants is 18.7 percentage points 
lower than whites, while the difference is 14.9 percentage points for Hispanics compared to 
whites.  Being older and female increased the chance of receiving an antidepressant.  Two other 
factors that increase the probability are obesity and having a higher level of education.  Insurance 
is an important factor in determining antidepressant use.  
<INSERT TABLE 3> 
Comparing the white sample to black sample regressions, there is some significant 
variation in the size and direction of the coefficient estimates, particularly for the variables of 
education, obesity, and health insurance.  While whites with some college education are 8.5 
percentage points more likely to use an antidepressant than whites with a high school education, 
for blacks some college reduced the chance of using an antidepressant by 32.6 percentage points.  
For those without a high school education, whites are four percentage points less likely to use an 
antidepressant than whites with a high school degree.  In contrast, blacks without a high school 
education are 3.5 percentage points more likely to use an antidepressant than those with a high 
school education, but the effect of not having a high school degree is not statistically significant 
for both groups.  Obesity is found to increase the probability of using an antidepressant in both 
groups, but the effect is four times larger for blacks than for whites.  Finally, having Medicare 
increased the probability of using a drug for both groups, but blacks are over 49.3 percent more 
likely to use a drug if they have Medicare.   
Hispanics had coefficient estimates that are more comparable to whites than blacks 
except in three cases.  First, the effect of being a male Hispanic is larger than for white males.  14 
 
White males are 8.9 percent less likely to obtain an antidepressant than white females, but for 
Hispanics the effect is a 14.9 percent reduction.  Second, Hispanics with below a high school 
education are less likely to use antidepressants than whites with similar education.  Hispanics 
without a high school degree are 14.1 percent less likely to use antidepressants than Hispanics 
with a high school education.  This compares to whites without a high school education only 
being 4 percent less likely to use antidepressants than whites with a high school degree.  Finally, 
Hispanics that self-report poor physical and mental health status have higher odds of using an 
antidepressant than Hispanics that do not report poor health status.  Whites are about three 
percent more likely to use antidepressants if they reported poor physical or mental health 
compared to whites that do not report poor health status, but both results are insignificant.  
Compared to Hispanics that do not report poor health status, Hispanics that reported poor 
physical health are 13.2 percent more likely to use an antidepressant, while Hispanics that 
reported poor mental health are 32 percent more likely to use an antidepressant.  This variation in 
the effect of health status between white and Hispanics could be due to differences in the 
manifestation of the symptoms of depression, the level of severity of depression before treatment 
is sought, or differences in self-reported measures of health (Myers et al., 2002).  
The comparison of the average characteristics and the coefficient estimates in Tables 2 
and 3 find there is significant variation by racial/ethnic group.  The decomposition results 
between whites and blacks and between whites and Hispanics are presented in Table 4.  The first 
row decomposes the aggregate disparity into the characteristics and coefficients effects.  The 
aggregate effect for blacks compared to whites find that 97.5% of the disparity in the use of 
antidepressants between the two groups can be explained by differences in their coefficients, 
while only 2.5% of the disparity is explained by differences in their characteristics.  This means 15 
 
that if blacks had the same coefficient estimates as whites, then 16.3 percentage points of the 
16.7 percentage point difference between black and white utilization of antidepressants among 
those reporting being diagnosed with depression would not exist.  This has important 
consequences for reducing the disparity in the use of antidepressants between whites and blacks.  
Although blacks on average have lower socio-economic status and less generous insurance 
coverage than whites, the source of the disparity is not the differences in the characteristics but 
how the characteristics affect the rate of use compared to whites.  
To further understand which characteristics and coefficients are different, the aggregate 
effect is broken down into sub-aggregate effects.  This allows for identification of which group 
of variables are driving the variation.  The disparity in antidepressant use between depressed 
whites and depressed blacks is almost entirely explained by the coefficients effect and, as 
expected, none of the sub-aggregate characteristics effects are statistically significant.  The sub-
aggregate coefficients effects of education and income are negative and statistically significant.  
These results suggest that if the effect of education and income were the same for blacks as 
whites, then the disparity would be larger.  In fact, if blacks with similar education as whites had 
the same coefficients as whites, the disparity would increase by 8.9 percentage points.   In the 
case of the sub-aggregate effects of health status including obesity and insurance variables, the 
coefficients effects are positive and statistically significant.  This means behavior by blacks and 
whites towards antidepressants is different even if they have similar insurance coverage.  For 
example, depressed blacks with Medicare are fifty percent more likely to receive an 
antidepressant, but the effect for depressed whites with Medicare is only five percent.  This 
suggests that blacks and whites that are not on Medicare have significantly different access to 
antidepressants.  Therefore, if blacks have similar coefficients as whites for health variables, the 16 
 
disparity would decrease by 18.8 percentage points, causing depressed blacks to use more 
antidepressants than depressed whites.  These results suggest that blacks and whites with similar 
levels of education and insurance coverage have significantly different rates of antidepressant 
use and efforts to reduce the disparity need to focus on why the two groups behave substantially 
different. 
<INSERT TABLE 4> 
In contrast, the aggregate difference in the proportion that used antidepressants between 
whites and Hispanics was 21.5 percentage points.  Of this difference, 32.7% is explained by the 
characteristics effect and 67.3% is explained by the coefficients effect.  Both are statistically 
significant at the 1% level.  This suggests that although the majority of the differences between 
Hispanics and whites are due to their coefficients, about one-third of the disparity is associated 
with differences in the characteristics of depressed Hispanics and depressed whites.  This is in 
contrast to the disparity between whites and blacks which is almost exclusively explained by 
coefficients effect.   Consequentially, this means that attempts to improve disparities between 
Hispanics and whites need to focus on why Hispanics have different rates of use as whites with 
similar characteristics, as well as eliminating differences in the average characteristics of 
Hispanics and whites.  This later effort to eliminate differences in the average characteristics 
may be harder if those differences are not modifiable (i.e. age or gender).  
In the case of depressed Hispanics compared to depressed whites, the aggregate effect 
suggests that majority of the disparity can be explained by the coefficients effect.  Nonetheless, 
the only sub-aggregate coefficients effect found to be statistically significant is obesity.  Obese 
Hispanics are 1.7 percentage points more likely to receive an antidepressant than obese whites.   
If Hispanics had the same coefficient for obesity as whites, sixty-two percent of the disparity 17 
 
between whites and Hispanics would disappear.  Therefore, same as the case for the difference 
between blacks and whites, interventions to reduce the disparity between Hispanics and whites 
need to focus on why obesity impacts the use of antidepressants differently for each group.  
However, unlike the case for the blacks and whites, we also have to pay attention to the 
difference in characteristics between Hispanics and whites since one-third of the disparity is 
explained by the characteristics effect.  When we break down the overall effect into sub-
aggregate level, there are four sub-aggregate characteristics effects that are statistically 
significant.  Depressed Hispanics tend to be younger, female, and are less likely to have a high 
school or college degree.  If Hispanics have similar demographic characteristics as whites then 
the disparity between the two groups would be reduced by slightly less than one percent point, 
while if Hispanics had similar education levels as whites, then the disparity would be 2.7 
percentage points smaller.  Both results are marginally significant.  Further, Hispanics are more 
likely to be uninsured or on Medicaid, and report poor health than their white counterparts.  If 
differences in reported health status and insurance coverage would disappear, then the disparity 
between whites and Hispanics would be 2.7 percentage points smaller.  Further, Hispanics and 
whites have different regional distributions, which account for 2 percentage points of the 
disparity.  Although the characteristics effect only explains one-third of the disparity, there are 
multiple characteristics that are modifiable by public policies.  In particular, providing better 
insurance coverage and improving educational opportunities to Hispanics could reduce the 
disparity by 5.4 percentage points, or about 25%. 
  In order to test the robustness of these results, we repeat the analysis for two additional 
diseases, high cholesterol and hypertension, but only report the aggregate effects.
14  Again, each 
regression is restricted to a sample that self-reports having the disease and the dependent variable 
                                                 
14 Full logit estimates and decomposition results are available upon request from the authors.   18 
 
is a binary indicator for receipt of a specific class of drugs for that disease. Using indicator 
variables of race/ethnicity in the pooled regression, disparities are found to exist in the use of 
statins for high cholesterol and hypertensive drugs for high blood pressure.  In the high 
cholesterol sample, blacks have a 4.7 percentage point lower probability of receiving a statin 
than whites and the difference for Hispanics 6.6 percentage points lower compared to whites.  
The result is statistically significant at the 5% level for Hispanics.  In contrast, for hypertensive 
drugs, blacks have a 12.8 percentage point lower probability of receiving a hypertensive drug 
than whites, while Hispanics use fewer hypertensive drugs than whites (3.6 percentage points).  
This result is statistically significant at the 1% level for blacks but was not significant for 
Hispanics.   
  The aggregate decomposition results for all three samples are reported in Table 5.  
Similar to the use of antidepressants, the disparity between blacks and whites in the use of statins 
for high cholesterol is almost entirely explained by the coefficients effect.  In fact, if blacks had 
the same coefficients as whites, blacks would use more statins than whites, while if blacks had 
the same characteristics as whites the disparity would get larger.  Both results are statistically 
insignificant.  In the case of Hispanics, both the characteristics and coefficients effects are 
statistically significant.  Of the 14.3 percent disparity between Hispanics and whites in the use of 
statins for high cholesterol, 46.7% is explained by the characteristics effect, and the remaining 
53.3% is explained by the coefficients effect.   
For the use of hypertensive drugs for high blood pressure, the majority of the disparity 
between blacks and whites is attributed to the coefficients effect (86.6%).  However, unlike the 
other two treatments, blacks also have a statistically significant aggregate characteristics effect.  
If blacks with self-reported high blood pressure had the same characteristics as whites with self-19 
 
reported high blood pressure, the disparity is reduced by 2.0 percentage points.  The disparity 
between Hispanics and whites is approximately equally split between the aggregate 
characteristics and coefficients effects, but neither effect is statistically significant.  
<INSERT TABLE 5> 
 
5. Discussion and Conclusion 
  Advancing our understanding of the factors that drive racial/ethnic disparities and how 
these factors could be different depending on the race/ethnicity of individual and the disease 
being treated can help in devising appropriate public policies.  Our decomposition analysis 
suggests that blacks are largely different from whites through the coefficients effect once they 
are diagnosed with a medical condition.  This means that public policies that attempt to reduce 
the disparities between whites and blacks in the use of drug therapy should focus on why blacks 
with characteristics similar to whites behave differently.  In the analysis of antidepressant use, 
the differences in coefficient estimates for the education and health-related variables compared to 
whites are important in determining the source of the disparity.  Since these differences most 
likely arise because of modifiable behaviors, it is important for policy-maker and researchers to 
understand and ask questions, such as, why do depressed blacks with higher levels of education 
have different rates of use of antidepressants than depressed whites with similar education?   
Some of the difference between white and black antidepressant use is reflected in cultural 
differences and social stigma related to depression (Givens et al, 2007).
15  Blacks may be more 
reliant on informal support networks or other alternative support mechanisms, such as ministers, 
reducing the likelihood of using antidepressant therapy as a first option for treatment compared 
                                                 
15 For example, Akerlof and Kranton (2000) have examined the effect of the experience of widespread and 
substantial discrimination on group identity and behavior.   20 
 
to other racial/ethnic groups (Taylor and Chatters, 1991; Taylor et al, 1996).  Another possible 
reason these disparities in receipt of medical care exist, particularly among blacks, could be due 
to distrust of physicians and their general perception of physicians.
16 These perceptions could 
have caused blacks to distrust the medical system and exacerbated racial/ethnic differences in the 
perceived efficacy of prescription drugs.  This means that attempts to reduce disparities in the 
use of drug therapy between white and blacks needs to focus on the education of the risks of 
leaving medical conditions untreated and to break down barriers, such as trust in physicians, that 
make minorities hesitant of accepting the efficacies of drug treatment.   
In contrast, the disparity between Hispanics and whites is rooted in both characteristics 
and coefficients effects.  In particular one-third to one-half of the disparity between Hispanics 
and whites is explained by differences in the characteristics effect.  The sources of some of the 
disparity between whites and Hispanics are able to be reduced either through modifying behavior 
or reducing differences in socio-economic status.  For example, Hispanics are younger than 
whites and younger persons are less likely to take and adhere to prescriptions therapies.  Public 
policy focusing on educating the young about the efficacy of drugs would mitigate the disparity 
between whites and Hispanics.  Besides focusing on demographic differences, Hispanics are less 
likely to have private insurance and are more likely to be uninsured or on Medicaid.  Clearly, this 
is an access and quality of health insurance issue.  In the case of uninsured, disparities could be 
reduced by expanding incentives for employers to provide insurance or to significantly improve 
coverage through the expansion of public programs.  For those covered by Medicaid, physicians 
could locate in areas in which it is harder for Medicaid recipients to access them.  This could be 
                                                 
16 Doescher et al. (2000) found that minority group members reported less positive perception of physicians than 
whites while Darity (2003) found that perceptions of racism can have an impact on well-being. 21 
 
solved by increasing reimbursement or providing other incentives for physicians to locate in 
primarily Medicaid neighborhoods. 
In the development of national health policy, it is critical to understand the factors that 
attribute to the significant variation in utilization of health care across the races and ethnicities.  
The Oaxaca-type decomposition for discrete-choice outcomes that analyzes the use of 
prescription drug therapy not only allows for identification of the existence and size of 
racial/ethnic disparities, but also identifies what may be the underlying factors that cause the 
disparity.  Further, by using the decomposition for different races and ethnicities, the method 
identifies how the determinants of disparities could vary for different groups.  We find that the 
disparity between white and blacks in the use of prescription drug therapy can largely be 
explained by differences in the coefficients effect, while the disparity between whites and 
Hispanics is split between the coefficients and characteristics effects.  A caveat of this study is 
that although this paper has focused on disparities among whites, blacks and Hispanics, we 
should be aware that there is also significant heterogeneity within each population.
17  Further 
research is needed to determine if the effects found are uniform among all segments of the 
Hispanic and black populations.  However, these results do suggest that the determinants of 
disparities can be different for specific racial and ethnic groups, and public policy may need to 
be tailored to the specific group to reduce disparities.   
 
                                                 
17 In the Hispanic population, Puerto Ricans have been found to experience health disparities while Mexicans have 
health advantages depending on the health outcome measure (Zsembik and Fennell, 2005).  In the black population, 
Caribbean blacks have been found to have lower rates of treatment for major depressive disorder than African 
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Pharmacologic Use
Whites Blacks Hispanics Blacks Hispanics
68.10% 51.39% 46.57% 16.71% 21.53%
82.30% 78.26% 68.03% 4.04% 14.27%
66.15% 51.50% 61.26% 14.65% 4.89%
Samples are restricted to adult individuals that self-report being told by a doctor they have a specific 
medical condition.  A patient is considered treated if they report filling a prescription in the drug class for the 
medical condition.
Treated with Statin Conditional on High 
Cholestrol Diagnosis
Treated with Hypertensive Drug 
Conditional on Hypertension Diagnosis
Table 1: Descriptive Statistics: Pharmacologic Use, By Race/Ethnicity
Difference compared to 
Whites
Treated with Antidepressant 














Age 48.102 15.691 45.199 14.013 44.173 15.396
Age Squared (100's) 25.599 15.752 22.384 13.363 21.876 14.571
Male 0.314 0.464 0.231 0.423 0.269 0.444
Married 0.509 0.500 0.245 0.431 0.475 0.500
Education Variables
Less than High School 0.160 0.367 0.278 0.449 0.534 0.500
College Education 0.203 0.402 0.120 0.326 0.060 0.237
Income 
Income (1,000's) 25.376 26.482 15.765 20.077 12.644 15.521
Obesity
Overweight BMI 0.310 0.462 0.269 0.444 0.352 0.478
Obese BMI 0.330 0.470 0.449 0.499 0.340 0.475
Health Variables
Report Poor Physical Health 0.319 0.466 0.444 0.498 0.403 0.491
Report Poor Mental Health 0.060 0.238 0.111 0.315 0.072 0.258
# Heart Disease Conditions 0.481 0.772 0.556 0.745 0.367 0.633
Medicare Insurance 0.233 0.423 0.171 0.378 0.143 0.351
Medicaid Insurance 0.169 0.375 0.449 0.499 0.355 0.479
Private Insurance 0.689 0.463 0.394 0.490 0.367 0.483
Region Variables
Northeast 0.160 0.367 0.148 0.356 0.152 0.360
Midwest 0.264 0.441 0.222 0.417 0.081 0.273
South  0.359 0.480 0.519 0.501 0.322 0.468
West 0.216 0.412 0.111 0.315 0.445 0.498
MSA 0.731 0.444 0.801 0.400 0.899 0.302
Sample Size 1483 216 335
Whites Blacks Hispanics
Table 2: Descriptive Statistics: Depression Sample, By Race/Ethnicity












Intercept -1.562 *** N.M. -1.551 *** N.M. -4.709 *** N.M. -1.972 N.M.
(0.470) (0.558) (1.688) (1.271)
Demographic Variables
Age 0.099 *** 0.023 *** 0.094 *** 0.020 *** 0.194 *** 0.048 *** 0.104 ** 0.026 **
(0.019) (0.004) (0.023) (0.005) (0.067) (0.017) (0.050) (0.012)
Age Squared (100's) -0.095 *** -0.022 *** -0.086 *** -0.018 *** -0.210 *** -0.052 *** -0.107 * -0.027 *
(0.020) (0.005) (0.024) (0.005) (0.074) (0.018) (0.055) (0.014)
Male -0.390 *** -0.092 *** -0.405 *** -0.089 *** 0.367 0.091 -0.600 ** -0.146 **
(0.108) (0.026) (0.126) (0.028) (0.381) (0.092) (0.287) (0.068)
Married 0.077 0.018 0.065 0.014 -0.277 -0.069 0.222 0.055
(0.105) (0.024) (0.125) (0.027) (0.377) (0.094) (0.266) (0.066)
Education Variables
Less than High School -0.253 ** -0.059 * -0.183 -0.040 0.143 0.035 -0.571 ** -0.141 **
(0.128) (0.030) (0.168) (0.037) (0.393) (0.097) (0.270) (0.066)
College Education 0.306 ** 0.068 ** 0.422 *** 0.085 *** -1.415 *** -0.326 *** 0.319 0.080
(0.146) (0.031) (0.164) (0.031) (0.561) (0.108) (0.533) (0.132)
Income 
Income (1,000's) -0.002 0.000 -0.003 -0.001 0.016 * 0.004 * -0.006 -0.001
(0.002) (0.001) (0.003) (0.001) (0.009) (0.002) (0.009) (0.002)
Obesity
Overweight BMI 0.121 0.028 0.148 0.031 0.054 0.014 0.071 0.018
(0.120) (0.027) (0.142) (0.030) (0.429) (0.107) (0.299) (0.074)
Obese BMI 0.256 ** 0.058 ** 0.227 0.048 0.822 ** 0.202 ** 0.261 0.065
(0.123) (0.028) (0.147) (0.030) (0.397) (0.094) (0.302) (0.075)
Health Variables
Report Poor Physical Health 0.153 0.035 0.123 0.026 -0.159 -0.040 0.533 * 0.132 **
(0.116) (0.026) (0.142) (0.030) (0.351) (0.087) (0.276) (0.068)
Report Poor Mental Health 0.474 ** 0.102 ** 0.137 0.029 0.577 0.140 1.393 ** 0.320 *
(0.213) (0.042) (0.259) (0.053) (0.518) (0.119) (0.569) (0.106)
# Heart Disease Conditions -0.014 -0.003 0.022 0.005 -0.062 -0.015 0.036 0.009
(0.077) (0.018) (0.090) (0.019) (0.266) (0.066) (0.221) (0.055)
Medicare Insurance 0.115 *** 0.115 *** 0.263 0.054 2.634 *** 0.493 *** 0.598 0.148
(0.187) (0.039) (0.220) (0.044) (0.699) (0.077) (0.511) (0.124)
Medicaid Insurance 0.154 0.035 0.102 0.022 0.334 0.083 0.209 0.052
(0.146) (0.033) (0.189) (0.039) (0.432) (0.107) (0.315) (0.079)
Private Insurance 0.341 *** 0.079 *** 0.377 ** 0.082 ** 0.348 0.086 0.370 0.092
(0.130) (0.030) (0.156) (0.035) (0.474) (0.117) (0.302) (0.075)
Region Variables
Midwest -0.287 * -0.067 * -0.335 * -0.073 * -0.251 -0.063 -0.081 -0.020
(0.163) (0.039) (0.188) (0.042) (0.521) (0.130) (0.549) (0.136)
South  0.081 0.019 0.079 0.017 0.380 0.095 0.124 0.031
(0.153) (0.035) (0.184) (0.039) (0.490) (0.121) (0.402) (0.100)
West -0.414 *** -0.098 ** -0.424 ** -0.094 ** 0.364 0.089 -0.452 -0.112
(0.158) (0.038) (0.192) (0.044) (0.611) (0.147) (0.374) (0.092)
MSA -0.387 *** -0.086 *** -0.335 ** -0.069 ** -0.799 * -0.191 ** -0.649 -0.160
(0.124) (0.027) (0.139) (0.028) (0.437) (0.098) (0.418) (0.100)
Race
Black -0.771 *** -0.187 ***
(0.162) (0.040)
Hispanic -0.619 *** -0.149 ***
(0.143) (0.035)
Sample Size 2034 1483 216 335
Pseudo R-Squared 0.077 0.053 0.138 0.104
***, **, * denote significance at the 1%, 5%, and 10% levels, respectively.
Table 3: Logit Regression Results: Depression Sample
Pooled Whites Blacks Hispanics
The sample is restricted to adult individuals that self-report being told by a doctor they are depressed. 
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Estimate Share Estimate Share Estimate Share Estimate Share
Aggregate Effect 0.004 2.52 0.163 *** 97.48 0.070 *** 32.69 0.145 *** 67.31
(0.013) (0.035) (0.019) (0.034)
Sub-Aggregate Effects
Demographic Variables -0.004 -2.41 -0.378 -226.23 0.008 * 3.54 -0.001 -0.53
(0.010) (0.369) (0.005) (0.272)
Education Variables 0.013 7.76 -0.089 *** -53.09 0.027 * 12.70 0.012 5.41
(0.009) (0.031) (0.014) (0.036)
Income -0.006 -3.70 -0.069 * -41.38 -0.008 -3.51 0.009 4.31
(0.007) (0.037) (0.007) (0.029)
Obesity -0.010 -6.21 0.030 * 18.09 -0.004 -1.78 0.134 ** 62.26
(0.009) (0.066) (0.004) (0.066)
Health Variables 0.023 13.65 0.188 *** 112.19 0.027 ** 12.42 0.031 14.51
(0.014) (0.069) (0.012) (0.049)
Region Variables -0.011 -6.57 0.041 24.27 0.020 ** 9.33 0.040 18.48
(0.009) (0.048) (0.008) (0.049)
Intercept 0.000 0 0.441 263.63 0.000 0 -0.080 -37.12
(0.361) (0.279)
***, **, * denote significance at the 1%, 5%, and 10% levels, respectively.
Table 4: Decomposition of Difference in Treatment of Depression with Antidepressants: Depression Sample
Difference Between Whites and Blacks Difference Between Whites and Hispanics
Characteristics Effect Coefficients Effect Characteristics Effect Coefficients Effect
Notes: The sample is restricted to adult individuals that self-report being told by a doctor they are depressed.  Estimate is calculated 
as the amount of the difference in treatment with antidepressants between two racial/ethnic groups that can be explained by 





Estimate Share Estimate Share Estimate Share Estimate Share
Treated with Antidepressant Conditional on Depression Diagnosis
Aggregate Effect 0.004 2.52 0.163 *** 97.48 0.070 *** 32.69 0.145 *** 67.31
(0.013) (0.035) (0.019) (0.034)
Treated with Statin Conditional on High Cholestrol Diagnosis
Aggregate Effect -0.005 -13.59 0.046 113.59 0.067 *** 46.66 0.076 ** 53.34
(0.009) (0.028) (0.021) (0.036)
Treated with Hypertensive Drug Conditional on Hypertension Diagnosis
Aggregate Effect 0.020 ** 13.40 0.127 *** 86.60 0.024 48.19 0.025 51.81
(0.010) (0.028) (0.021) (0.036)
***, **, * denote significance at the 1%, 5%, and 10% levels, respectively.
Notes: Samples are restricted to adult individuals that self-report being told by a doctor they have a specific medical condition.  A 
patient is considered treated if they report filling a prescription in the drug class for the medical condition.  Each estimate is 
calculated as the amount of the difference in treatment with reciept of pharmacotherapy between two racial/ethnic groups that can be 
explained by differences in the characteristics or coefficient of both groups.  The share refers to the proportion of the difference 
explained by estimate.  
Table 5: Aggregate Effect of Decomposition of Difference in Treatment: All Samples
Difference Between Whites and Blacks Difference Between Whites and Hispanics
Characteristics Effect Coefficients Effect Characteristics Effect Coefficients Effect
 